ArticleJournal of cardiothoracic surgery2026
Effectiveness and safety of drug-coated balloon in patients with acute ST-segment elevation myocardial infarction during interventional therapy.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis investigation seeks to assess the efficacy and safety profile of drug-coated balloon (DCB) and drug-eluting stent (DES) throughout primary percutaneous coronary intervention (PCI) among individuals with ST-segment elevation myocardial infarction (STEMI).
methodsThe medical records of 142 STEMI patients receiving emergency PCI in our hospital between January 2019 and April 2024 underwent retrospective examination. Per the intervention strategy, patients were split into the observation group (n = 85, DCB therapy) and the control group (n = 131, DES therapy). The study compared several parameters between these cohorts: the occurrence of target lesion revascularization and major adverse cardiovascular events (MACE) within one week, measurements of left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and the frequency of slow-flow post-PCI. Additionally, these parameters (excluding slow-flow), along with late lumen loss (LLL) and bleeding incidents, were evaluated during a nine-month follow-up period.
resultsThere were no notable variations in postoperative LVEDd, LVEF, incidence rates of slow-flow, target lesion revascularization, and MACE within one week between the two groups. After the ten-month follow-up, there were no notable variations in LLL, incidence rates of target lesion revascularization (6.87% VS. 4.71%), MACE (35.11% VS. 31.76%), and hemorrhage (8.40% VS. 2.35%) between the control group and observation group.
conclusionIn individuals with STEMI undergoing emergency percutaneous coronary intervention, the short and long-term prognoses of drug-coated balloons are not inferior to those of drug-eluting stents, which are safe and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.